Propanc Biopharma Receives Certificate of Grant for PRP Foundation Patent from Canadian Intellectual Property Office
PRP Dosing & Method to Treat Cancer Stem Cells Patents Validated in Countries Across Europe Resulting in Growing IP Portfolio of 87 patents
Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, has recently achieved a significant milestone. The company announced that it has received a Certificate of Grant for its PRP Foundation Patent from the Canadian Intellectual Property Office.
This latest development further solidifies Propanc’s position in the field of cancer research and treatment. The PRP Foundation Patent covers the dosing and method to treat cancer stem cells, a crucial aspect of developing effective cancer therapies. With this patent now validated in countries across Europe, Propanc’s intellectual property portfolio has grown to include a total of 87 patents.
Impact on Individuals:
For individuals battling cancer, Propanc’s innovative approach to treatment offers hope for better outcomes. By focusing on cancer stem cells, which are known to drive tumor growth and metastasis, Propanc’s therapies have the potential to target the root cause of the disease. This could lead to more personalized and effective treatment options for patients facing recurring or metastatic cancer.
Impact on the World:
Propanc’s continued success in obtaining patents for its groundbreaking research not only showcases the company’s dedication to advancing cancer care but also contributes to the global effort to combat this devastating disease. With an expanded IP portfolio that now includes key markets in Europe, Propanc is poised to make a significant impact on the field of oncology and bring new hope to cancer patients around the world.
Conclusion:
Propanc Biopharma’s recent Certificate of Grant for the PRP Foundation Patent from the Canadian Intellectual Property Office marks a major achievement for the company and underscores its commitment to developing innovative cancer treatments. With a growing IP portfolio and a focus on targeting cancer stem cells, Propanc is well-positioned to make a meaningful difference in the lives of patients and contribute to the global fight against cancer.
